RNA
Atrium Therapeutics, Inc.
7.80$
-3.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1,693.2% | 28.0% | 18.1% | 33.6% | 30.4% | 24.8% | – | 3,590.5% | – | 174.2% | 0.8% | 11.4% | – | |
| -1,593.2% | 72.0% | 81.9% | 66.4% | 100.0% | 100.0% | 100.0% | -3,490.5% | 100.0% | 100.0% | 99.2% | 88.6% | 98.6% | |
| 1,693.2% | 2,408.4% | 1,886.3% | 3,126.7% | 3,304.7% | 3,216.4% | 6,324.9% | 3,590.5% | 1,242.1% | 2,153.3% | 84.8% | 510.8% | 571.1% | |
| 487.2% | 735.0% | 392.3% | 1,013.7% | 996.3% | 953.2% | 2,136.0% | 958.3% | 46.3% | 3,538.6% | 103.2% | 342.2% | 185.4% | |
| 487.2% | 3,115.4% | 2,260.5% | 4,106.8% | 4,300.9% | 4,169.6% | 8,460.9% | 958.3% | 67.8% | 5,692.0% | 187.2% | 841.5% | 331.9% | |
| -2,080.4% | -3,043.5% | -2,178.6% | -4,040.4% | -4,200.9% | -4,069.6% | -8,360.9% | -4,448.7% | -67.8% | -5,592.0% | -88.0% | -752.9% | -268.0% | |
| – | 17.8% | – | – | – | – | – | – | – | – | – | – | – | |
| -1,858.0% | -2,756.2% | -1,943.4% | -3,461.8% | -3,441.7% | -3,439.5% | -7,360.0% | -4,089.3% | -67.8% | -5,592.0% | -84.7% | -672.0% | -259.4% | |
| -222.9% | 0.0% | 16.9% | – | – | – | – | – | -1.4% | 4.0% | – | – | – | |
| -1,858.0% | -2,756.2% | -1,943.4% | -3,461.8% | -3,441.7% | -3,439.5% | -7,360.0% | -4,089.3% | -66.4% | -5,595.9% | -84.7% | -672.0% | -259.0% | |
| -2,060.3% | -3,015.4% | -2,160.5% | -4,006.8% | -4,170.5% | -4,044.8% | -8,311.0% | -4,427.6% | -67.3% | -5,577.8% | -83.9% | -741.5% | -264.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.